Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRITR) by De Santis, R et al.
Novel antitenascin antibody with increased tumour localisation for
Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT)
R De Santis*
,1, AM Anastasi
1, V D’Alessio
1, A Pelliccia
1, C Albertoni
1, A Rosi
1, B Leoni
1, R Lindstedt
1,
F Petronzelli
1, M Dani
2, A Verdoliva
2, A Ippolito
2, N Campanile
2, V Manfredi
2, A Esposito
2, G Cassani
2,
M Chinol
3, G Paganelli
3 and P Carminati
1
1Immunology Department, Sigma Tau SpA R&D, Via Pontina Km 30.400, 00040 Pomezia, Rome, Italy;
2Tecnogen SCpA Localita ` La Fagianeria, Piana di
Monte Verna, 81015 Caserta, Italy;
3Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy
The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a
biotinylated antibody, avidin/streptavidin and
90Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin
antibody BC4, previously used for clinical applications, was found not suitable for further development because of the production of
an additional, nonfunctional light chain. In order to solve this problem, the new cST2146 hybridoma clone was generated. The
monoclonal antibody ST2146, produced by this hybridoma, having the same specificity as BC4 but lacking the nonfunctional light
chain, was characterised. ST2146 was found able to bind human tenascin at an epitope strictly related, if not identical, to the antigenic
epitope of BC4. It showed, compared to BC4, higher affinity and immunoreactivity and similar selectivity by immunohistochemistry.
Biodistribution studies of biotinylated ST2146 and three other monoclonal antitenascin antibodies showed for ST2146 the highest
and more specific tumour localisation in HT29-grafted nude mice. On the overall, ST2146 appears to be a good alternative to BC4
for further clinical development of PAGRIT.
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The specificity of tumour therapies is often a limiting factor in
determining the success of a treatment. In fact, the onset of toxic
effects and the reduced tolerability of certain anticancer agents
limit their use and affect the quality of life of patients.
The reduction of toxicity is directly related to the selectivity of
treatment for cancer cells. Monoclonal antibodies (Mabs) can be
used for specific targeting of tumours, and when combined with
the avidin/biotin amplification system they constitute a powerful
and selective way to deliver active moieties to the tumour site.
A three-step Pretargeted Antibody-Guided RadioImmunoTher-
apy (PAGRIT) approach for systemic and locoregional treatment
of brain tumours was previously shown to be safe and to produce
clinical benefits to patients (Cremonesi et al, 1999; Paganelli et al,
1999, 2001; Grana et al, 2002).
PAGRIT is based on intravenous, sequential administration of
biotinylated monoclonal antibodies, avidin/streptavidin and
90yt-
trium (
90Y)-labelled biotin. The selectivity of the three-step
pretargeting approach relies on the use of a biotinylated mono-
clonal antitenascin antibody. Tenascin-C is an extracellular matrix
protein, which is abundant in the stroma of several solid tumours
(Natali et al, 1991; Mackie, 1997). It is a hexameric glycoprotein
that can undergo alternative splicing resulting in large (up to
320kDa monomer) or small (220kDa monomer) isoforms. The
large tenascin variant, which is preferentially expressed in malignant
tissues, has been shown to exert anti-adhesive effects thus
favouring tumour metastasis (Jahkola et al, 1998; Ghert et al,
2001). Moreover, tenascin expression, similar to vascular endo-
thelial growth factor/vascular permeability factor expression, is
spatially and temporally related to neovascularisation (Zagzag and
Capo, 2002). An immunosuppressive activity has also been
reported for the large tenascin domain FnIIIA1A2 on activation-
induced T-lymphocyte proliferation and cytokine production in
vitro (Puente Navazo et al, 2001). These features of tumour-
associated tenascin make this protein a good candidate for tumour
targeting. Moreover, the targeting of extracellular matrix, com-
pared to the targeting of tumour cell surface antigens, exhibits the
advantage of being unaffected by antigen modulation of tumour
cells, thus representing an ideal way for antitumour therapy. The
role of the biotinylated antitenascin antibody is to display biotins
at the tumour site in order to mediate subsequent streptavidin and
90Y-biotin accumulations.
The monoclonal antitenascin antibodies BC4 and BC2 described
by Siri et al (1991) and Balza et al (1993) have been previously
used, with success, in both systemic and topical, pretargeted or
direct therapeutic settings in patients with brain tumours (Riva
et al, 1997; Paganelli et al, 1999, 2001; Grana et al, 2002). However,
both BC2 and BC4 hybridoma clones were found unsuitable for
process development because of the production of an additional,
nonfunctional light chain (most likely of parental myeloma origin)
whose increased level of expression in the scaled-up cultivation
prevented a large-scale antibody purification (Vola et al (1993) and
results from our laboratories). In order to generate a new
hybridoma cell clone with the specificity of BC4 but lacking the
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lexpression of nonfunctional light chains, mice were immunised
with the recombinant EGF-like repeat fragment of tenascin
previously shown to contain the BC4 antigenic epitope (Balza
et al, 1993). Hybridoma supernatants were screened on purified
tenascin and the antibody ST2146 was selected. Both in vitro and
in vivo characterisations of ST2146 showed that it might be a good
alternative to BC4.
MATERIALS AND METHODS
Hybridomas and monoclonal antibodies
BC4 and BC2 hybridomas were kindly provided by Dr Luciano
Zardi (Laboratory of Cell Biology, Istituto Nazionale per la Ricerca
sul Cancro, Genova, Italy) and the related monoclonal antibodies,
both of IgG1/k isotype, were purified from the hybridoma culture
supernatants by protein A chromatography followed by hydro-
xylapatite chromatography as described by Vola et al (1993).
ST1897 (IgG1/k isotype) was obtained from Wistar Institute,
Philadelphia, PA, USA (original code 300-2; Herlyn et al, 1991). In
order to generate new hybridoma cell clones with the specificity of
BC4, Balb/c mice were immunised with pTn28 E. coli phage lysate.
pTn28 is a lgt11 recombinant clone encoding a fragment of the
EGF-like repeats of human tenascin previously shown to contain
the BC4 epitope (Balza et al, 1993). pTn28 immunised splenocytes
were fused to Sp2/0Ag14 nonproducing myeloma cells (obtained
from ECACC, Italy) by standard methods (Cianfriglia et al, 1986).
The hybridoma population was screened by ELISA on purified SK-
MEL-28 (human melanoma cell line obtained from Interlab Cell
Line Collection (ICLC), Genova, Italy) tenascin. Tenascin-specific
hybridomas were cloned by limiting dilution two times in FCS
containing medium and three times in protein-free medium
(Animal Derived Component Free Medium HyClone, HyQ
R
Perbio). The cST2146 subclone was selected for the production
of the cST2146 Master Cell Bank (MCB) and Working Cell Bank
(WCB). MCB samples were deposited at the ICLC, Genova, Italy for
patent purposes and the patent application 60/359.299 was
submitted in US.
ST2146 production and purification
The production of Mab ST2146 was performed by cultivation of
cST2146 hybridoma cells in protein-free medium, in a 2l perfusion
bioreactor (MD2, B Braun). The stability of cST2146 Post
Production Cell Bank (PPCB) was confirmed by FACS analysis
and by limiting dilution. The ST2146 isotype was determined by
the use of a commercial kit (Mouse-hybridoma subtyping kit,
Boehringer Mannheim, Monza, Italy). Purification was performed
by three chromatography steps. The 10 concentrated bioreactor
harvest was loaded on MEP HyperCell column (BioSepra, Cergy,
Saint Christopher, France) in 50mM TRIS pH 8.0. The column was
washed with five bed volumes of binding buffer and the retained
material eluted by 50mM sodium acetate, pH 4.0. The eluted
material, adjusted to pH 8.0 with 1 M TRIS, was loaded on a
Q-Sepharose-XL column (Pharmacia, Milan, Italy) equilibrated
with 50mM TRIS, pH 8.0; elution was performed with 50mM
sodium acetate, 250mM NaCl, pH 6.0. The final SP-Sepharose-XL
chromatography was performed by loading the material eluted
from Q-Sepharose and adjusting pH to 5.0, and then eluting with
0.1 M sodium bicarbonate, 0.5 M NaCl, pH 8.5, a condition useful
for the next step of antibody biotinylation.
ST2146 deglycosylation
To investigate the heavy-chain heterogeneity of ST2146, the Mab,
at a concentration of 1mgml
 1, was digested with 1.5Uml
 1 of
sialidase (Sigma, Milan, Italy) in 10mM NaHPO4, 150mM NaCl, pH
6.4, at 37
oC for 24h. The digested and not digested samples were
subjected to electrophoresis on 12% polyacrylamide slab gels and
stained with Coomassie Brilliant Blue.
Hydroxylapatite chromatography
The separation of the three immunoglobulin variants of BC4
was done essentially as described by Vola et al (1993). Briefly,
hydroxylapatite chromatography analysis was carried out by
loading 100–300mg of protein A-purified BC4 or ST2146 onto a
1ml Macro-Prep Ceramic Hydroxylapatite Type II (20mm)
column, 10 6mm
2 (BIO-RAD, Milan, Italy) equilibrated at a
flow rate of 0.5mlmin
 1 with 10mM sodium phosphate, pH 6.8.
Elution was performed with a concentration gradient of phosphate
buffer (10–150mM in 50min).
Western blot analysis
Human tenascin purified from SK-MEL-28 cell supernatant as
previously described (Saginati et al, 1992), purified A–D fragment
and pTn28 phage lysate (kindly provided by Dr L Zardi) were run
on 12% reducing, SDS–PAGE and transferred onto a nitrocellulose
membrane by electroblotting. After protein transfer, the mem-
brane was incubated overnight at +41C in 0.1 M TRIS, 0.15 M NaCl,
5% dried milk, to block nonspecific binding. After five washings
with the same blocking buffer, the membrane was incubated for
1.5h at room temperature with BC4, BC2 or ST2146 diluted in PBS
at 5mgml
 1. After washings, a goat anti-mouse IgG-alkaline phos-
phatase conjugate (Amersham, Milan, Italy), diluted 1:1000 in
blocking buffer, was used incubating for 1h at room temperature;
after three washings with 0.1 M TRIS, 0.1 M NaCl, 0.08 M MgCl2, the
chromogenic substrate solution, consisting of 0.330mgml
 1 nitro
blue tetrazolium (Sigma, Milan, Italy), 0.165mgml
 1 5-bromo-4-
chloro-3-indolyl phosphate in blocking buffer, was employed.
Immunoreactivity and competitive ELISA
Immunot MAXISORP 96-well plates (Nunc) were coated at 41C
overnight with 100mlwell
 1 of tenascin solution at 5 or 0.5mgml
 1
in PBS, pH 7.2. Tenascin was purified from the culture supernatant
of the melanoma cell line SK-MEL-28 as described previously.
After coating, the plates were washed once with PBS, 0.1% Tween
20 (washing buffer) and blocked with 300mlwell
 1 of PBS, 0.1%
Tween 20, 1% BSA (blocking and diluting buffer) for 2h at room
temperature. Plates were used immediately or dried and frozen at
 201C. For immunoreactivity analysis the plates were incubated
with serial dilutions of antitenascin Mabs (100mlwell
 1) for 1.5 h
at 371C. Each dilution was assayed in duplicate. After three wash-
ings, the plates were incubated for 1.5h at 371C with 100mlwell
 1
of anti-mouse IgG (Fc-specific) alkaline phosphatase-conjugated
(SIGMA, St. Louis, IL, USA) diluted 1:1000 in blocking buffer. The
plates were then washed four times, incubated with 200mlwell
 1 of
pNPP (SIGMA, St. Louis, IL, USA) for 30min at 371C, stopped with
100mlwell
 1 of 3 M NaOH and read with an ELISA spectro-
photometer (SEAC Sirio S) at 405nm. For competitive ELISA, the
biotinylated monoclonal antibody ST2146 (IgG2b) was mixed with
increasing concentrations of ST2146, BC4 (IgG1), or a not related
IgG1 (SIGMA, St. Louis, IL, USA) as competitors; 100mlwell
 1 of
this mixture was plated on tenascin-coated plates. Optimal con-
centrations of tenascin and biotinylated ST2146 were determined
in preliminary experiments. After 2h at room temperature, the
plates were washed three times, incubated for 30min at room tem-
perature with 100mlwell
 1 of horseradish peroxidase–streptavidin
(Amersham, Milan, Italy) diluted 1:1500 in blocking buffer, washed
again and incubated for 30min at room temperature with
200mlwell
 1 of TMB substrate (SIGMA, St. Louis, IL, USA). The
reaction was stopped with 100mlwell
 1 of 0.5M H2SO4 and the plate
read with an ELISA spectrophotometer (SEAC Sirio S) at 405 nm.
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BIAcoreX instrument, CM5 sensorchip, HBS buffer (10mM Hepes,
0.15mM NaCl, 3.4mM EDTA and 0.005% surfactant P20, pH 7.4),
amine coupling kit (NHS, N-hydroxysuccinimide; EDC, N-ethyl-
N0dimethylaminopropylcarbodiimide) and ethanolamine were all
obtained from Biosense (Milan, Italy). Tenascin was immobilised
on a CM5 sensor chip as follows. A continuous flow of HBS at
5mlmin
 1 was maintained and the carboxymethylated dextran-
coated surface was activated by a 7-min injection of a solution
containing 200mM EDC and 50mM NHS followed by the injection
of tenascin (82mgml
 1 in 10mM sodium acetate brought to pH 2.3
with HCl). Capping of unreacted sites was achieved by injecting 1 M
ethanolamine, pH 8.5, for 7min. Excess tenascin was washed off
with repeated injections of 100mM NaOH. The final immobilisa-
tion response was 3200 resonance units (RU). Sensorgrams were
generated by the injection of Mabs (at five concentrations ranging
from 3.9nM to 500nM) in HBS at a flow rate of 30mlmin
 1. The
binding was not affected by the flow rate (tested between 5 and
30mlmin
 1) suggesting no mass transport limitation for the Mab
binding. Kinetic data were collected in duplicate for each con-
centration of Mab. The association and dissociation times were 60
and 120s, respectively. The chip was regenerated by injection of
repeated pulses of 100mM NaOH until the difference between the
baseline before and after injection was less than 10RU. Biosensor
data were prepared, modelled and fitted by means of the BIA-
evaluation 3.1 software. The evaluation of the data was done using
a bivalent-analyte model with simultaneous determination of asso-
ciation and dissociation constants. The quality of the fitted data
was evaluated by comparison between calculated and experimental
curves (residual values) and by the magnitude of the w
2 parameter.
Immunohistochemistry
Immunohistochemistry studies were conducted on tissue array
slides (SuperBioChips Laboratories, Korea) including various
human tumours and normal organs. Slides were processed
according to the manufacturer’s instructions and binding was
revealed by the use of the Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA). Briefly, after deparaffination and hydra-
tion, the tissue sections were blocked with normal blocking serum.
Slides were then incubated overnight at 41C with BC4 or ST2146 at
10 and 2mgml
 1 in PBS, respectively. After three washings with
PBS and incubation for 30min with a biotinylated goat anti-mouse
antibody, the slides were incubated for 30min with the avidin–
biotin–peroxidase complex. After three washings with PBS, DAB
substrate was added and the reaction was stopped after 2min by
washing in tap water. Counterstaining was performed by Mayer’s
haematoxylin for 10s. Negative controls included slides incubated
with an isotype-matched, nonrelevant antibody or with only the
second antibody.
Radiolabelling of Mabs and animal study
Antibodies at 200–400mgml
 1 were mixed with chloramine T
(Sigma, Milan, Italy) at a final concentration of 2–10mgml
 1 and
with 1–4 mCi (37–148kBq) of sodium
125iodine (New Life Science,
Milan, Italy) per microgram of antibody. After 5–10min at room
temperature, the reaction mixture was buffer exchanged three
times with 1.0ml of sterile PBS on Vivaspin membrane, cut off
30000 (Sartorius, Germany) to remove free iodine. Immunor-
eactivity of radiolabelled antibodies was checked by ELISA as
described in the ‘Immunoreactivity and competitive ELISA’ section
under Materials and Methods on plates coated with tenascin at
1.0mgml
 1. Balb/c nu/nu mice (Charles River, Calco, Como, Italy)
were transplanted subcutaneously (s.c.) with 5 10
6 HT29 human
colon carcinoma cells (obtained from DSMZ, Germany) in 0.1ml
of PBS. After 15 days, mice were randomised into treatment groups
(five animals/group) and intravenously (i.v.) injected with 2mgo f
125I-radiollabeled antibodies (1–2 10
6c.p.m.animal
 1). Normal
mouse immunoglobulins (Sigma, Milan, Italy) were used as a
control. After 48 and 72h from injection mice were killed
by cervical dislocation and blood, spleen, kidney, liver and
tumour mass collected. Each tissue was weighted and counted in a
g-counter (Packard, Canberra). Data were expressed as the
percentage of injected doseg
 1 of tissue (% i.d.g
 1). The data
were statistically analysed by the Student’s t method.
The care and husbandry of animals were in accordance with the
European Directive 86/609 and with Italian legislation.
RESULTS
Generation and in vitro characterisation of ST2146
In order to generate a BC4-like monoclonal antibody, hybridomas
were produced from mice immunised with the recombinant pTn28
phage lysate encoding the EGF-like repeats of human tenascin
previously shown to contain the BC4 antigenic epitope. Figure 1
shows the schematic representation of human tenascin, the related
recombinant pTn28 and A–D antigenic fragments, as well as the
strategy used to generate a BC4-like antibody. ST2146 was purified
pTn28 phage Iysate immunisation
Screening of hybridoma supernatants by ELISA
on purified tenascin
BC4
pTn28
2HN
EGF-like repeats  Fibronectin-like repeats Fibrinogen-like repeats
1 234 5 A1A2 A3 A4 B C D 678 COOH
BC2
A_D
Figure 1 Schematic representation of human tenascin-C, pTn28 and A–D recombinant fragments and strategy to generate a BC4-like antibody.
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chromatography steps and was found to be of the IgG2b/k isotype.
Biochemical characterisation The homogeneity of ST2146 was
evaluated by hydroxylapatite chromatography which showed a
single peak for ST2146 as opposed to three peaks observed for BC4
(Figure 2, panels A and B). By reducing SDS–PAGE analysis, the
hydroxylapatite peak of ST2146 proved to be homogeneous for
light-chain composition while a certain degree of heterogeneity for
the heavy chain was apparent (Figure 2, panel C, lane 1). This
observation was consistent with the variability in O-linked
glycosylation previously reported for the murine IgG2b/k isotype
(Kim et al, 1994). Consistency in the pattern of the ST2146 heavy-
chain bands was observed in three different batches obtained from
FCS-containing or protein-free culture media (data not shown).
The glycosidic nature of the ST2146 heavy-chain variability was
confirmed by digesting the antibody with sialidase, which caused
the disappearance of the higher molecular weight band (Figure 2,
panel C, lane 2). The SDS–PAGE analysis of the hydroxylapatite
peaks of BC4 showed the heterogeneous composition of this Mab,
with peak 1 containing a light chain of higher molecular weight
compared to the light chain of peak 3 (Figure 2D, lanes P1 and P3),
and peak 2 composed of both high and low molecular weight light
chains (Figure 2D, lane P2).
Specificity and immunoreactivity ST2146 binds to human tenas-
cin at an epitope strictly related, if not identical, to the antigenic
epitope of BC4, as shown by Western blotting in Figure 3A, which
indicates that BC4, BC2 and ST2146 are all recognising tenascin
(lane C of panels i–iii) with BC4 and ST2146 reactive with the
EGF-like repeats region of tenascin (pTn28 in lane A of panels i–
iii) and BC2 reactive with the A–D region (lane B of panels i–iii).
Competition binding data in Figure 3B indicate a lower
immunoreactivity of BC4 compared to ST2146 as the amount of
BC4 inhibiting 50% binding of ST2146 to tenascin is about 10
times that of ST2146. This result was also confirmed by direct
ELISA. Figure 4 shows that the amount of ST2146 giving 1.0 o.d. by
ELISA in condition of optimal tenascin coating (panel A), is
approximately 20 times less than the amount of divalent BC4 (peak
3 of Figure 2B) and approximately 100 times less than that of BC4
(pool of peaks 1–3). This difference in immunoreactivity is
dramatically amplified in conditions of antigen limitation, as
shown in panel B of Figure 4, where only ST2146 maintains
significant immunoreactivity.
Affinity The affinities of ST2146, BC4, BC2 and ST1897 were
evaluated by BIAcore on a tenascin-coated chip. The sensorgrams
as well as the kinetic values of Figure 5 indicate for ST2146 the
most rapid antigen association followed by ST1897, BC4 and BC2.
The dissociation rate of ST2146 was the lowest followed by BC4,
ST1897 and BC2. The antigen binding kinetics indicate for ST2146
the highest affinity for the human tenascin within the panel of
antibodies tested. The higher number of RU observed with BC4 and
BC2 might be consistent with the presence of a significant fraction
of monovalent immunoglobulins in BC4 and BC2 antibody batches
which might lead to an overall higher amount of bound antibody
compared to divalent immunoglobulins ST2146 and ST1897.
Immunohistochemistry Immunohistochemistry with ST2146 was
performed in parallel to BC4 on tissue array slides that included 20
different tumours and more than 60 normal tissues. BC4 and
ST2146 showed similar selectivity. In fact, both antibodies strongly
react with the stroma of several solid tumours including breast,
liver, lung and rectum carcinomas reported as examples in
Figure 6. ST2146 and BC4 also detect tenascin in the interstitium
of several normal tissues (data not shown) as previoulsy published
for BC4 (Natali et al, 1991).
Biodistribution
To address the pharmacology behaviour of ST2146 and to evaluate
its ability to localise at the tumour mass, comparative biodistribu-
tion studies of
125I-labelled ST2146, BC4, BC2 and ST1897 were
performed in nude mice grafted with tenascin expressing human
ST2146
kDa
kDa
41.8
30.6
17.8
C
A
Heavy chain
Light chain
D
45
31
21.5
P1 P2 P3 12
15 20 25 30 35
P1 P2
P3
BC4 B
Figure 2 Hydroxylapatite chromatography of ST2146 (A) and BC4 (B). SDS–PAGE analysis under reducing conditions of ST2146 not digested (C, lane
1) or digested with sialidase (C, lane 2) and BC4 peaks 1, 2 or 3 from hydroxylapatite chromatography (D, P1, P2 and P3, respectively). Note: The dotted
chain was found to be not functional. Therefore, divalent BC4 corresponds only to peak 3.
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lcolon carcinoma HT29. The reactivity of the antitenascin
antobodies on HT29 was preliminary confirmed by immuno-
histochemistry. The staining pattern that resulted was very similar
for all antibodies tested while the isotype-matched controls were
negative (data not shown). The immunoreactivity of radiolabelled
antibodies evaluated by ELISA was found to be at least 80% that of
each unlabelled one (data not shown). The results in Figure 7A
show that after 48h from injection, the %i.d.g
 1 of tumour of
antitenascin Mabs ranges between 6 and 9% compared to 4% of the
normal mouse IgG. After 72h from injection, ST2146 showed
approximately 16% of the i.d.g
 1 of tumour compared to about
8% of either BC2 or ST1897 or less than 5% of BC4 antibodies. The
highest concentration of ST2146 in the tumour, within the panel of
antibodies tested at both 48 and 72h from injection, is associated
with the lowest amount on either blood, spleen, kidney or liver
(Figure 7B–E). The highest tumour accumulation of ST2146
together with the lowest accumulation on nontarget tissues results
in the most favourable tumour/nontumour (T/NT) ratios at both
48 and 72h as shown in Figure 8A, B and indicate that this Mab is
the best at specific tumour targeting within the panel of
antitenascin monoclonal antibodies tested in the present study.
Particularly, at 72h, the amount of ST2146 on the tumour is about
twice the amount still present in the blood and more than seven
times the amount present in liver, spleen and kidney. Additional
biodistribution data produced with ST2146 biotinylated with
different biotin/Mab ratios indicate that about 10–15% i.d.g
 1
of tumour is maintained up to 10 days while the T/NT ratios
increase up to three times vs the blood and more than 20 vs either
liver, spleen or kidney independent of the extent of antibody
biotinylation (manuscript in preparation).
DISCUSSION
The main objective of pretargeting is to maximise the accumula-
tion of drugs or radioisotopes at the tumour site while minimising
distribution at nontarget organs. The potency and the selectivity of
the monoclonal antibody are essential prerequisites for optimal
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Figure 3 (A) Western blot analysis of BC2 (i), BC4 (ii) and ST2146 (iii) antibodies. A: pTn28; B: A–D fragment; C: tenascin. (B) Competitive ELISA.
Biotinylated ST2146 was mixed with increasing concentrations of ST2146, BC4 or a not related IgG1 as competitors and plated on tenascin-coated plates.
Binding was measured after addition of horseradish peroxidase–streptavidin and related chromogenic substrate.
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lpretargeting. The previously established monoclonal antibodies
BC4 and BC2 proved to be useful for tumour targeting and
pretargeting in several clinical trials. BC4 recognises an epitope
within the EGF-like repeats of human tenascin. This epitope is
shared by both small and large tenascin isoforms. BC2 recognises
only the large tenascin being directed towards an epitope within
the alternatively spliced A–D region which is absent in the small
tenascin variant. Although Mabs that do not discriminate between
small and large tenascin, like BC4, should more likely crossreact
with normal tissues, previous immunohistochemical analysis of
BC4 and BC2 reactivities on a large panel of normal tissues
indicated a substantial similarity on the recognition patterns for
the two antibodies (Natali et al, 1991), thus legitimating the idea
that the crossreactivity of BC4 with normal tissue tenascin might
be operationally overcome by the overexpression of tenascin of
neoplastic tissues. In fact, biodistribution data from clinical trials
showed that pretargeting with BC4 results in about 25 times more
radioactivity on the tumour than on non-tumour tissues (Paganelli
et al, 1999), while no biodistribution data are available for BC2.
The good tumour/non tumour distribution ratio of BC4 in patients
could be the result of either efficient chasing which in the three-
step method reduces the nonspecific distribution, or could be
because of overexpression of tenascin on the tumour compared to
normal tissues, or both. On the other end, the frequency and level
of expression of the tenascin epitopes derived from alternative
splicing are not yet fully elucidated. In fact, a previous
immunohistochemistry study, with two recombinant antitenascin
antibodies, showed that 96 different tumours, including brain,
breast and lung, were all strongly positive with the antibody
recognising an epitope shared by small and large tenascins, while
only 28 were positive with the other antibody recognising an
epitope within the alternatively spliced region (Carnemolla et al,
1999). Taking into account clinical results with BC4 in the three-
step method (Paganelli et al, 1999; Grana et al, 2002), we decided
to generate a BC4-like antibody as a first priority while also
pursuing the selection of a BC2-like antibody to better address the
issue of optimal tenascin targeting in future studies. Advances in
pretargeting biotechnology have been recently reviewed by Good-
win and Meares (2001). Besides the encouraging clinical results of
Paganelli’s group in brain tumours with the three-step method,
others pursuing a two-step pretargeting method also obtained high
efficacy in tumour therapy in the animal model (Axworthy et al,
2000) and encouraging clinical results in colon and lung cancers
using a streptavidin–Mab conjugate (Breitz et al, 1999, 2000; Knox
et al, 2000). The two methods share the fundamental concept of
using monoclonal antibodies for tumour pretargeting while dif-
fering in several aspects. The procedure to obtain the streptavidin–
Mab conjugate, used in the two-step method, requires a chemical
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lderivatisation of streptavidin, reduction and reoxidation of the
Mab and the separation of the streptavidin–Mab conjugate from
unconjugated streptavidin by chromatography. This procedure is
more complex than the antibody biotinylation of the three-step
method, which requires a simple chemical reaction followed by
buffer exchange and which is therefore more suitable to industrial
development. Moreover, speculating about the potency of the two
conjugates, the biotinylated-Mab (three-step method) might be
superior to the streptavidin–Mab (two-step method) as the several
biotins on the antibody might allow the binding of more than the
single avidin present in the conjugate of the two-step method.
However, the three-step treatment is obviously more cumbersome
to develop than the two-step one, requiring one additional step
and one additional chasing that increases the products to be
sequentially administered from three to five. In the present study,
we found that the ST2146 monoclonal antibody exhibits higher
immunoreactivity than BC4, BC2 and ST1897. The highest
immunoreactivity of ST2146 is consistent with its homogeneity
BC4 ST2146
Breast carcinoma Liver adenocarcinoma Breast carcinoma Liver adenocarcinoma
Lung squamous carcinoma Rectum adenocarcinoma Lung squamous carcinoma Rectum adenocarcinoma
Figure 6 Immunohistochemistry on serial sections of breast, liver, lung and rectum carcinomas with BC4 and ST2146 antibodies.  20 magnification.
20
18
16
14
12
10
8
6
4
2
0
Mouse IgG BC2 BC4 ST1897 ST2146
Tumour
(P<0.001)
(P<0.01) (P<0.01)
(P<0.01)
(P<0.05)
(P<0.01)
48 h 72 h
A
48 h 72 h
16
12
4
8
0
Mouse IgG BC2 BC4 ST1897 ST2146
Blood B
48 h 72 h
8
6
2
4
0
Mouse IgG BC2 BC4 ST1897 ST2146
Spleen C
48 h 72 h
%
 
i
.
d
.
 
g
_
1
%
 
i
.
d
.
 
g
_
1
%
 
i
.
d
.
 
g
_
1
%
 
i
.
d
.
 
g
_
1
%
 
i
.
d
.
 
g
_
1
4
3
1
2
0
Mouse IgG BC2 BC4 ST1897 ST2146
Kidney D
48 h 72 h
8
6
2
4
0
Mouse IgG BC2 BC4 ST1897 ST2146
Liver E
Figure 7 Biodistribution of
125I-labelled ST2146, BC4, BC2, ST1897 and
normal mouse IgG. Data represent the mean values, 7standard error, of
the % of injected dose per gram of tissue (%i.d.g
 1) from five animals at 48
or 72h. P-values were obtained vs normal mouse IgG by Student’s t-test.
5.0
48 h
4.0
3.0
2.0
1.0
0.0
T
/
N
T
 
r
a
t
i
o
Blood Spleen Kidney Liver
Mouse IgG BC2 BC4 ST1897 ST2146
A
Mouse IgG BC2 BC4 ST1897 ST2146
72 h
8.0
6.0
4.0
2.0
0.0
T
/
N
T
 
r
a
t
i
o
Blood Spleen Kidney Liver
B
Figure 8 Tumour/nontumour ratios of
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las opposed to the BC4 and BC2 nonhomogeneity and is associated
with the highest affinity among the antibodies tested. The highest
affinity of ST2146 also correlates with the highest in vitro binding
capacity in condition of antigen limitation. This feature is
particularly important in relation to the intended use of ST2146
as tumour pretargeting agent. In fact, previous animal studies from
Zuckier et al (2000) indicated that a low-density antigen can be
effectively targeted only by high-affinity antibodies. Our present
data confirm that ST2146 exhibits the highest tumour-targeting
capacity in nude mice xenograft models compared to three other
monoclonal antitenascin antibodies, including BC2 and BC4. We
believe that ST2146 might be a good candidate for further clinical
development of PAGRIT.
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